Released Mar 14, 2014, after the close
10-K filed Mar 14, 2014, 73 days after period end · 0001171843-14-001247
Q4 2013 · 10-K
Revenue$27.85M$27.85M −1.4% vs Q4 2012+10.8% vs Q3 2013
Net Income-$756.00K-$756.00K N/M vs Q4 2012N/M vs Q3 2013
EPS Diluted-$0.02-$0.02 N/M vs Q4 2012N/M vs Q3 2013
Gross Profit$12,048,000−10.0%
Operating Income-$949,000N/M
Operating Cash Flowderived$1,249,000−11.2%
Margins · derived
Gross margin43.3%−4.2 pt vs Q4 2012
Operating margin-3.4%−11.0 pt vs Q4 2012
Net margin-2.7%−7.0 pt vs Q4 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2013 | Q4 2012 | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | $27.85M | $28.25M | $29.03M | — |
| Net Income | -$756.00K | $1.20M | $738.00K | — |
| EPS Diluted | -$0.02 | $0.04 | $0.02 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR